Medicare Enrolled

Dr. Adam Bagley, M.D.

Rheumatology · Orange Park, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
2100 KINGSLEY AVE, Orange Park, FL 32073
9042760001
In practice since 2010 (16 years)
NPI: 1649595216 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Bagley from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bagley? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Bagley

Dr. Adam Bagley is a rheumatology in Orange Park, FL, with 16 years in practice. Based on federal Medicare data, Dr. Bagley performed 225,558 Medicare services across 1,917 unique beneficiaries.

Between the years covered by Open Payments, Dr. Bagley received a total of $24,443 from 51 pharmaceutical and/or device companies across 1233 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Bagley is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 16 years in practice▲ Top 7% volume in FL$ $24,443 industry payments

Medicare Practice Summary

Medicare Utilization ↗
225,558
Medicare services
Top 7% in FL for rheumatology
1,917
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~14,097 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Tocilizumab injection (Actemra)138,260$5$15
Golimumab infusion (Simponi Aria)36,631$10$37
Abatacept infusion (Orencia)23,750$33$111
Injection, rituximab, 10 mg8,650$60$211
Injection, belimumab, 10 mg5,719$35$124
Infliximab infusion (Remicade)5,042$26$90
Denosumab injection (Prolia/Xgeva)3,120$19$56
Office visit, established patient (30-39 min)998$88$320
Blood draw (venipuncture)627$8$16
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less574$46$166
Administration of chemotherapy into vein, 1 hour or less519$92$335
Steroid injection (triamcinolone)388$1$4
Administration of chemotherapy into vein, each additional hour347$20$72
Injection of additional new drug or substance into vein213$11$40
Injection, zoledronic acid, 1 mg140$7$21
Drug injection, under skin or into muscle132$11$36
New patient office visit (45-59 min)115$121$423
Injection, diphenhydramine hcl, up to 50 mg104$1$4
Injection, methylprednisolone sodium succinate, up to 125 mg92$4$14
Office visit, established patient, complex (40-54 min)78$136$454
Office visit, established patient (20-29 min)23$65$228
Infusion, normal saline solution, 250 cc23$1$2
Injection of drug or substance into vein13$29$97
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
29.3% high complexity
69.9% medium
0.8% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$24,443
Total received (2018-2024)
Avg $3,492/year across 7 years
Top 20% in FL for rheumatology
51
Companies
1,233
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$20,249 (82.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,642 (10.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,552 (6.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,933
2023
$3,891
2022
$4,519
2021
$3,276
2020
$2,027
2019
$4,901
2018
$2,897

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Horizon Therapeutics plc
$3,538
Janssen Biotech, Inc.
$3,176
Amgen Inc.
$2,870
Novartis Pharmaceuticals Corporation
$1,730
UCB, Inc.
$1,461
PFIZER INC.
$907
GlaxoSmithKline, LLC.
$899
AstraZeneca Pharmaceuticals LP
$893
Genentech USA, Inc.
$877
AbbVie Inc.
$778
E.R. Squibb & Sons, L.L.C.
$697
ABBVIE INC.
$644
GENZYME CORPORATION
$545
AbbVie, Inc.
$544
Lilly USA, LLC
$526
Boehringer Ingelheim Pharmaceuticals, Inc.
$525
Alexion Pharmaceuticals, Inc.
$341
Mallinckrodt Hospital Products Inc.
$340
Octapharma USA, Inc.
$337
ANI Pharmaceuticals, Inc.
$325
Sobi, Inc
$318
Radius Health, Inc.
$297
Ferring Pharmaceuticals Inc.
$198
SOBI, INC
$198
Flexion Therapeutics, Inc.
$170
Horizon Pharma plc
$156
Aurinia Pharma U.S., Inc.
$134
Mallinckrodt Enterprises LLC
$130
Janssen Scientific Affairs, LLC
$120
Johnson & Johnson Health Care Systems Inc.
$94
Sandoz Inc.
$72
DePuy Synthes Sales Inc.
$70
Grifols USA, LLC
$69
Mallinckrodt LLC
$69
Ultragenyx Pharmaceutical Inc.
$40
Kiniksa Pharmaceuticals, Ltd.
$39
Celgene Corporation
$35
ARBOR PHARMACEUTICALS, INC.
$33
Actelion Pharmaceuticals US, Inc.
$32
CSL Behring
$30
Takeda Pharmaceuticals U.S.A., Inc.
$28
Hikma Pharmaceuticals USA
$28
SANOFI-AVENTIS U.S. LLC
$23
Organon LLC
$21
Kyowa Kirin, Inc.
$15
Ironwood Pharmaceuticals, Inc
$13
Pacira Therapeutics, Inc.
$12
West-Ward Pharmaceuticals
$12
Sebela Pharmaceuticals Inc.
$12
MEDEXUS PHARMA, INC.
$11
ASSERTIO THERAPEUTICS, Inc.
$11
Top 3 companies account for 39.2% of total payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · Arcalyst · BENLYSTA · Bimzelx · COSENTYX · CRYSVITA · CUVITRU · CYLTEZO · Cimzia · Crysvita · EUFLEXXA · EVENITY · Enbrel · Gralise · HUMIRA · HYRIMOZ · Horizant · Humira · ILARIS · INFLECTRA · KEVZARA · KINERET · KRYSTEXXA · Kineret · LINZESS · LUPKYNIS · LYRICA · MONOVISC · Mitigare · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · Otezla · PENNSAID · PREVNAR 13 · PURIFIED CORTROPHIN GEL · Privigen · Prolia · RAYOS · REMICADE · RIDAURA · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · TALTZ · TAVNEOS · TREMFYA · Tavneos · Tymlos · ULTOMIRIS · UPTRAVI · XELJANZ · Xembify · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (83%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $11 per 100 Medicare services performed
Looking for a rheumatology in Orange Park?
Compare rheumatologys in the Orange Park area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
27
Per 100K population
12.1
County median income
$86,094
Nearest hospital
HCA FLORIDA ORANGE PARK HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Bagley is a mixed practice specialist, with above-average Medicare volume (top 7% in FL), and high industry engagement (low-engagement, top 20%), with 16 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Bagley experienced with tocilizumab injection (actemra)?
Based on Medicare claims data, Dr. Bagley performed 138,260 tocilizumab injection (actemra) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bagley receive payments from pharmaceutical companies?
Yes. Dr. Bagley received a total of $24,443 from 51 companies across 1,233 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bagley's costs compare to other rheumatologys in Orange Park?
Dr. Bagley's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bagley) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →